Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „letermovir“
Suchtreffer
Begriffe & Kennungen
Letermovir
Eintrag öffnenPrevymis · 4.5 · (CYP2C8 induction, CYP2C8 Concomitant use is not recommended. and OATP1B inhibition) When letermovir is co-adm
Eintrag öffnenPrevymis · 4.5 · (CYP2C8 induction, CYP2C8 Concomitant use is not recommended. and OATP1B inhibition) When letermovir is co-adm
Eintrag öffnenPrevymis · 4.5 · (CYP2C8 induction, CYP2C8 Concomitant use is not recommended. and OATP1B inhibition) When letermovir is co-adm
Eintrag öffnenPrevymis · 4.5 · (CYP3A, OATP1B1/3 When letermovir is co-administered with inhibition) cyclosporine, use of these statins is co
Eintrag öffnenPrevymis · 4.5 · (CYP3A, OATP1B1/3 When letermovir is co-administered with inhibition) cyclosporine, use of these statins is co
Eintrag öffnenPrevymis · 4.5 · (CYP3A, OATP1B1/3 When letermovir is co-administered with inhibition) cyclosporine, use of these statins is co
Eintrag öffnenPrevymis · 4.5 · (OATP1B1/3 and/or P-gp inhibition) (600 mg single dose ↔ letermovir intravenous)/ AUC 1.58 (1.38, 1.81) leterm
Eintrag öffnenPrevymis · 4.5 · (OATP1B1/3 and/or P-gp inhibition) (600 mg single dose ↔ letermovir intravenous)/ AUC 1.58 (1.38, 1.81) leterm
Eintrag öffnenPrevymis · 4.5 · (Sum of OATP1B1/3 and/or P-gp inhibition and P-gp/UGT induction) (600 mg once daily ↓ letermovir PO (24 hours
Eintrag öffnenPrevymis · 4.5 · (Sum of OATP1B1/3 and/or P-gp inhibition and P-gp/UGT induction) (600 mg once daily ↓ letermovir PO (24 hours
Eintrag öffnenPrevymis · 4.5 · (Sum of OATP1B1/3 and/or P-gp inhibition and P-gp/UGT induction) (600 mg once daily ↓ letermovir PO (24 hours
Eintrag öffnenPrevymis · 4.5 · -The estimated letermovir plasma exposure is different depending on the dose regimen used (see table in sectio
Eintrag öffnenPrevymis · 4.5 · -The estimated letermovir plasma exposure is different depending on the dose regimen used (see table in sectio
Eintrag öffnenPrevymis · 4.5 · -The estimated letermovir plasma exposure is different depending on the dose regimen used (see table in sectio
Eintrag öffnenPrevymis · 4.5 · 39 administration of letermovir may result in clinically relevant increases in the plasma concentrations of co
Eintrag öffnenPrevymis · 4.5 · 6 Additional effects of other products on letermovir relevant when combined with cyclosporine
Eintrag öffnenPrevymis · 4.5 · 7 Medicinal products transported by OATP1B1/3 Letermovir is an inhibitor of OATP1B1/3 transporters. Administra
Eintrag öffnenPrevymis · 4.5 · 72 Additional effects of other products on letermovir relevant when combined with cyclosporine
Eintrag öffnenPrevymis · 4.5 · 73 Medicinal products transported by OATP1B1/3 Letermovir is an inhibitor of OATP1B1/3 transporters. Administr
Eintrag öffnen